Cell therapy veteran Natalie Mount, Ph.D., brings more than 25 years of industry experience ST. LOUIS, MO and SAN DIEGO, CA, August 25, 2022- Wugen, Inc., a clinical-stage biotechnology company…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, July 19, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological…
Read More-- WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment immunosuppression relative to conventional natural killer (NK) cells -- -- WU-NK-101 demonstrated robust anti-tumor activity in vitro and in…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, June 1, 2022- Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, May 12, 2022 –Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, April 7, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, March 24, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…
Read More-- WU-CART-007 granted FDA Orphan Drug Designation for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL) ---- WU-CART-007 is the…
Read MoreST. LOUIS, MO and SAN DIEGO, CA, March 9, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of…
Read MoreWU-CART-007, an allogeneic off-the-shelf CAR-T cell therapy for T-Cell malignancies, has received IND clearance from the FDA WU-CART-007 demonstrates robust safety profile and exhibits strong CD7-specific anti-tumor activity in…
Read MoreCopyright © 2026 Wugen. All Rights Reserved.
Privacy Notice
a COGNEO design